The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract infection when administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results